KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Takeda Pharmaceutical (TAK) FCF Margin (2018 - 2025)

Historic FCF Margin for Takeda Pharmaceutical (TAK) over the last 8 years, with Q4 2025 value amounting to 34.81%.

  • Takeda Pharmaceutical's FCF Margin fell 59600.0% to 34.81% in Q4 2025 from the same period last year, while for Dec 2025 it was 15.68%, marking a year-over-year decrease of 12200.0%. This contributed to the annual value of 21.98% for FY2025, which is 45500.0% up from last year.
  • As of Q4 2025, Takeda Pharmaceutical's FCF Margin stood at 34.81%, which was down 59600.0% from 11.86% recorded in Q3 2025.
  • In the past 5 years, Takeda Pharmaceutical's FCF Margin registered a high of 54.06% during Q1 2021, and its lowest value of 1.64% during Q1 2025.
  • Its 5-year average for FCF Margin is 24.28%, with a median of 21.71% in 2023.
  • Its FCF Margin has fluctuated over the past 5 years, first soared by 624200bps in 2021, then tumbled by -226900bps in 2022.
  • Quarter analysis of 5 years shows Takeda Pharmaceutical's FCF Margin stood at 41.56% in 2021, then dropped by -10bps to 37.54% in 2022, then plummeted by -51bps to 18.42% in 2023, then surged by 121bps to 40.78% in 2024, then decreased by -15bps to 34.81% in 2025.
  • Its FCF Margin stands at 34.81% for Q4 2025, versus 11.86% for Q3 2025 and 22.39% for Q2 2025.